Phage therapy: A step forward in the treatment of Pseudomonas aeruginosa infections

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 7449-7456

  Pires, Diana P ^a   Boas, Diana Vilas ^a   Sillankorva, Sanna ^a   Azeredo, Joana ^a  

^a UNIVERSITY OF MINHO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; POLYMYXIN B; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENETIC ENGINEERING; GENETIC VARIABILITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MOLECULAR THERAPY; MULTIDRUG RESISTANCE; MYOVIRIDAE; NONHUMAN; PATIENT SAFETY; PHAGE THERAPY; PODOVIRIDAE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PSEUDOMONAS PHAGE; RISK BENEFIT ANALYSIS; SEQUENCE ANALYSIS; SHORT SURVEY; SIPHOVIRIDAE; SURVIVAL RATE; ANIMAL; BIOLOGICAL THERAPY; DISEASE MODEL; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VIROLOGY;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

ANIMALS; BIOLOGICAL THERAPY; DISEASE MODELS, ANIMAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES;

EID: 84937722537     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00385-15     Document Type: Short Survey

References (92)

1. Twort FW. 1915. An investigation on the nature of ultra-microscopic viruses. Lancet 186:1241-1243.http://dx.doi.org/10.1016/S0140-6736(01)20383-3.
2. d'Hérelle F. 1917. Sur un microbe invisible antagoniste des bacilles dysentériques. C R Hebd Seances Acad Sci Ser D 165:373-375.
3. Ceyssens P-J, Lavigne R. 2010. Bacteriophages of Pseudomonas. Future Microbiol 5:1041-1055. http://dx.doi.org/10.2217/fmb.10.66.
4. Clokie MR, Millard AD, Letarov AV, Heaphy S. 2011. Phages in nature. Bacteriophage 1:31-45. http://dx.doi.org/10.4161/bact.1.1.14942.
5. Azeredo J, Sillankorva S, Pires DP. 2014. Pseudomonas bacteriophage isolation and production, p 23-32. In Filloux A, Ramos J-L (ed), Pseudomonas methods and protocols. Humana Press, New York, NY.
6. Holmfeldt K, Solonenko N, Shah M, Corrier K, Riemann L, Verberkmoes NC, Sullivan MB. 2013. Twelve previously unknown phage genera are ubiquitous in global oceans. Proc Natl Acad Sci USA 110:12798-12803. http://dx.doi.org/10.1073/pnas.1305956110.
7. Guttman B, Raya R, Kutter E. 2004. Basic phage biology, p 29-66. In Kutter E, Sulakvelidze A (ed), Bacteriophages: biology and applications. CRC Press LLC, Boca Raton, FL.
8. Little J. 2005. Lysogeny, prophage induction, and lysogenic conversion, p 37-54. In Waldor M, Friedman D, Adhya S (ed), Phages: their role in bacterial pathogenesis and biotechnology. ASM Press, Washington, DC.
9. Bruynoghe R, Maisin J. 1921. Essais de thérapeutique au moyen du bacteriophage. C R Soc Biol 85:1120-1121.
10. d'Hérelle F. 1921. Le bactériophage: son rôle dans l'immunité. Masson et Cie, Paris, France.
11. Sulakvelidze A, Alavidze Z, Morris JG. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45:649-659. http://dx.doi.org/10.1128/AAC.45.3.649-659.2001.
12. Dublanchet A, Fruciano E. 2008. A short history of phage therapy. Med Mal Infect 38:415-420. http://dx.doi.org/10.1016/j.medmal.2008.06.016.
13. Chanishvili N. 2012. Phage therapy-history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res 83:3-40. http://dx.doi.org/10.1016/B978-0-12-394438-2.00001-3.
14. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122-S129. http://dx.doi.org/10.1038/nm1145.
15. Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417-433. http://dx.doi.org/10.1128/MMBR.00016-10.
16. Wright GD, Sutherland AD. 2007. New strategies for combating multidrug-resistant bacteria. Trends Mol Med 13:260-267. http://dx.doi.org/10.1016/j.molmed.2007.04.004.
17. Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28:591-595. http://dx.doi.org/10.1016/j.tibtech.2010.08.001.
18. Potera C. 2013. Phage renaissance: new hope against antibiotic resistance. Environ Health Perspect 121:a48-a53. http://dx.doi.org/10.1289/ehp.121-a48.
19. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S. 2005. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11:211-219. http://dx.doi.org/10.1007/s10156-005-0408-9.
20. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections. Bacteriophage 1:66-85. http://dx.doi.org/10.4161/bact.1.2.15845.
21. Kellenberger G, Kellenberger E. 1957. Electron microscopical studies of phage multiplication. Virology 3:275-285. http://dx.doi.org/10.1016/0042-6822(57)90093-4.
22. Holloway B, Egan J, Monk M. 1960. Lysogeny in Pseudomonas aeruginosa. Aust J Exp Biol Med Sci 38:321-330. http://dx.doi.org/10.1038/icb.1960.34.
23. Driscoll JA, Brody SL, Kollef MH. 2007. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67:351-368. http://dx.doi.org/10.2165/00003495-200767030-00003.
24. Mah T-F, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310. http://dx.doi.org/10.1038/nature02122.
25. Obritsch MD, Fish DN, MacLaren R, Jung R. 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353-1364. http://dx.doi.org/10.1592/phco.2005.25.10.1353.
26. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50:43-48. http://dx.doi.org/10.1128/AAC.50.1.43-48.2006.
27. Essoh C, Blouin Y, Loukou G, Cablanmian A, Lathro S, Kutter E, Thien HV, Vergnaud G, Pourcel C. 2013. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS One 8:e60575. http://dx.doi.org/10.1371/journal.pone.0060575.
28. Khairnar K, Raut MP, Chandekar RH, Sanmukh SG, Paunikar WN. 2013. Novel bacteriophage therapy for controlling metallo-beta-lactamase producing Pseudomonas aeruginosa infection in catfish. BMC Vet Res 9:264. http://dx.doi.org/10.1186/1746-6148-9-264.
29. McVay CS, Velásquez M, Fralick JA. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51:1934-1938. http://dx.doi.org/10.1128/AAC.01028-06.
30. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201:1096-1104. http://dx.doi.org/10.1086/651135.
31. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. 2011. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 6:e16963. http://dx.doi.org/10.1371/journal.pone.0016963.
32. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. 2010. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54:397-404. http://dx.doi.org/10.1128/AAC.00669-09.
33. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, Uchiyama J, Sakurai S, Matsuzaki S, Imai S, Yamaguchi K. 2007. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51:446-452. http://dx.doi.org/10.1128/AAC.00635-06.
34. Pereira SG, Rosa AC, Ferreira AS, Moreira LM, Proença DN, Morais PV, Cardoso O. 2014. Virulence factors and infection ability of Pseudomonas aeruginosa isolates from a hydropathic facility and respiratory infections. J Appl Microbiol 116:1359-1368. http://dx.doi.org/10.1111/jam.12463.
35. Wagner VE, Filiatrault MJ, Picardo KF, Iglewski BH. 2008. Pseudomonas aeruginosa virulence and pathogenesis issues, p 129-158. In Cornelis P (ed), Pseudomonas genomics and molecular biology. Caister Academic Press, Norfolk, United Kingdom.
36. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582-610. http://dx.doi.org/10.1128/CMR.00040-09.
37. Breidenstein EBM, de la Fuente-Núñez C, Hancock REW. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19: 419-426. http://dx.doi.org/10.1016/j.tim.2011.04.005.
38. CDC. 2013. Antibiotic resistance threats in the United States. CDC, Atlanta, GA.
39. Fajardo A, Martínez JL. 2008. Antibiotic resistance in Pseudomonas, p 177-211. In Cornelis P (ed), Pseudomonas genomics and molecular biology. Caister Academic Press, Norfolk, United Kingdom.
40. Fajardo A, Martínez-Martín N, Mercadillo M, Galán JC, Ghysels B, Matthijs S, Cornelis P, Wiehlmann L, Tümmler B, Baquero F, Martínez JL. 2008. The neglected intrinsic resistome of bacterial pathogens. PLoS One 3:e1619. http://dx.doi.org/10.1371/journal.pone.0001619.
41. Fernández L, Breidenstein EBM, Hancock REW. 2011. Creeping baselines and adaptive resistance to antibiotics. Drug Resist Updat 14:1-21. http://dx.doi.org/10.1016/j.drup.2011.01.001.
42. Ballok AE, O'Toole GA. 2013. Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+and Cl-flux in the lung. J Bacteriol 195:4013-4019. http://dx.doi.org/10.1128/JB.00339-13.
43. Strateva T, Mitov I. 2011. Contribution of an arsenal of virulence factors to pathogenesis of Pseudomonas aeruginosa infections. Ann Microbiol 61: 717-732. http://dx.doi.org/10.1007/s13213-011-0273-y.
44. Bjarnsholt T, Jensen PØ Jakobsen TH, Phipps R, Nielsen AK, Rybtke MT, Tolker-Nielsen T, Givskov M, Høiby N, Ciofu O. 2010. Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS One 5:e10115. http://dx.doi.org/10.1371/journal.pone.0010115.
45. Garcia-Medina R, Dunne WM, Singh PK, Brody SL. 2005. Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells. Infect Immun 73:8298-8305. http://dx.doi.org/10.1128/IAI.73.12.8298-8305.2005.
46. Moreau-Marquis S, Stanton BA, O'Toole GA. 2008. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther 21:595-599. http://dx.doi.org/10.1016/j.pupt.2007.12.001.
47. Anderson GG, Moreau-Marquis S, Stanton BA, O'Toole GA. 2008. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 76:1423-1433. http://dx.doi.org/10.1128/IAI.01373-07.
48. Drenkard E, Ausubel FM. 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740-743. http://dx.doi.org/10.1038/416740a.
49. Watnick P, Kolter R. 2000. Biofilm, city of microbes. J Bacteriol 182: 2675-2679. http://dx.doi.org/10.1128/JB.182.10.2675-2679.2000.
50. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418.1318.
51. Ackermann H-W. 2009. Phage classification and characterization. Methods Mol Biol 501:127-140. http://dx.doi.org/10.1007/978-1-60327-164-6_13.
52. Luiten RG, Putterman DG, Schoenmakers JG, Konings RN, Day LA. 1985. Nucleotide sequence of the genome of Pf3, an IncP-1 plasmidspecific filamentous bacteriophage of Pseudomonas aeruginosa. J Virol 56: 268-276.
53. Holland SJ, Sanz C, Perham RN. 2006. Identification and specificity of pilus adsorption proteins of filamentous bacteriophages infecting Pseudomonas aeruginosa. Virology 345:540-548. http://dx.doi.org/10.1016/j.virol.2005.10.020.
54. Olsthoorn RC, Garde G, Dayhuff T, Atkins JF, Van Duin J. 1995. Nucleotide sequence of a single-stranded RNA phage from Pseudomonas aeruginosa: kinship to coliphages and conservation of regulatory RNA structures. Virology 206:611-625. http://dx.doi.org/10.1016/S0042-6822(95)80078-6.
55. Ruokoranta TM, Grahn AM, Ravantti JJ, Poranen MM, Bamford DH. 2006. Complete genome sequence of the broad host range single-stranded RNA phage PRR1 places it in the Levivirus genus with characteristics shared with alloleviviruses. J Virol 80:9326-9330. http://dx.doi.org/10.1128/JVI.01005-06.
56. Hoogstraten D, Qiao X, Sun Y, Hu A, Onodera S, Mindich L. 2000. Characterization of phi8, a bacteriophage containing three doublestranded RNA genomic segments and distantly related to Phi6. Virology 272:218-224. http://dx.doi.org/10.1006/viro.2000.0374.
57. Qiao X, Qiao J, Onodera S, Mindich L. 2000. Characterization of phi 13, a bacteriophage related to phi 6 and containing three dsRNA genomic segments. Virology 275:218-224. http://dx.doi.org/10.1006/viro.2000.0501.
58. Gottlieb P, Wei H, Potgieter C, Toporovsky I. 2002. Characterization of phi 12, a bacteriophage related to phi 6: nucleotide sequence of the small and middle double-stranded RNA. Virology 293:118-124. http://dx.doi.org/10.1006/viro.2001.1288.
59. Pires D, Sillankorva S, Faustino A, Azeredo J. 2011. Use of newly isolated phages for control of Pseudomonas aeruginosa PAO1 and ATCC 10145 biofilms. Res Microbiol 162:798-806. http://dx.doi.org/10.1016/j.resmic.2011.06.010.
60. Torres-Barceló C, Arias-Sánchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. 2014. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One 9:e106628. http://dx.doi.org/10.1371/journal.pone.0106628.
61. Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L. 2013. Phageantibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Res Microbiol 164:55-60. http://dx.doi.org/10.1016/j.resmic.2012.08.008.
62. Zhang Y, Hu Z. 2013. Combined treatment of Pseudomonas aeruginosa biofilms with bacteriophages and chlorine. Biotechnol Bioeng 110:286-295. http://dx.doi.org/10.1002/bit.24630.
63. Gu J, Liu X, Li Y, Han W, Lei L, Yang Y, Zhao H, Gao Y, Song J, Lu R, Sun C, Feng X. 2012. A method for generation phage cocktail with great therapeutic potential. PLoS One 7:e31698. http://dx.doi.org/10.1371/journal.pone.0031698.
64. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol 8:769-783. http://dx.doi.org/10.2217/fmb.13.47.
65. Jaiswal A, Koley H, Ghosh A, Palit A, Sarkar B. 2013. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect 15:152-156. http://dx.doi.org/10.1016/j.micinf.2012.11.002.
66. Hall AR, De Vos D, Friman V-P, Pirnay J-P, Buckling A. 2012. Effects of sequential and simultaneous applications of bacteriophagesonpopulations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl Environ Microbiol 78:5646-5652. http://dx.doi.org/10.1128/AEM.00757-12.
67. Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S, Morita T, Muraoka A, Sumi T, Matsuzaki S, Daibata M, Fukushima A. 2012. Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PLoS One 7:e47742. http://dx.doi.org/10.1371/journal.pone.0047742.
68. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey A, Ross RP, Hill C. 2012. Bacteriophages ϕMR299-2 and ϕNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. mBio 3:e00029-12. http://dx.doi.org/10.1128/mBio.00029-12.
69. Tiwari BR, Kim S, Rahman M, Kim J. 2011. Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models. J Microbiol 49:994-999. http://dx.doi.org/10.1007/s12275-011-1512-4.
70. Heo Y-J, Lee Y-R, Jung H-H, Lee J, Ko G, Cho Y-H. 2009. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother 53:2469-2474. http://dx.doi.org/10.1128/AAC.01646-08.
71. Hawkins C, Harper D, Burch D, Anggård E, Soothill J. 2010. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol 146:309-313. http://dx.doi.org/10.1016/j.vetmic.2010.05.014.
72. Sivera Marza JA, Soothill JS, Boydell P, Collyns TA. 2006. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32:644-646. http://dx.doi.org/10.1016/j.burns.2006.02.012.
73. Sulakvelidze A, Kutter E. 2004. Bacteriophage therapy in humans, p 381-436. In Kutter E, Sulakvelidze A (ed), Bacteriophages: Biology and Applications. CRC Press LLC, Boca Raton, FL.
74. d'Herelle F. 1931. Bacteriophage as a treatment in acute medical and surgical infections. Bull N Y Acad Med 7:329-348.
75. Rice TB. 1930. Use of bacteriophage filtrates in treatment of suppurative conditions: report of 300 cases. Am J Med Sci 179:345-360.
76. Schless RA. 1932. Staphylococcus aureus meningitis: treatment with specific bacteriophage. AmJ Dis Child 44:813-822. http://dx.doi.org/10.1001/archpedi.1932.01950110115011.
77. Pirnay J-P, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R. 2011. The phage therapy paradigm: prêt-à-porter or sur-mesure?. Pharm Res 28:934-937. http://dx.doi.org/10.1007/s11095-010-0313-5.
78. Bruttin A, Brüssow H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874-2878. http://dx.doi.org/10.1128/AAC.49.7.2874-2878.2005.
79. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:237-238, 240-243. http://dx.doi.org/10.12968/jowc.2009.18.6.42801.
80. Weber-Dabrowska B, Mulczyk M, Górski A. 2001. Bacteriophage ther-apy for infections in cancer patients. Clin Appl Immunol Rev 1:131-134. http://dx.doi.org/10.1016/S1529-1049(01)00015-0.
81. Sarker SA, McCallin S, Barretto C, Berger B, Pittet A-C, Sultana S, Krause L, Huq S, Bibiloni R, Bruttin A, Reuteler G, Brüssow H. 2012. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434:222-232. http://dx.doi.org/10.1016/j.virol.2012.09.002.
82. Wright A, Hawkins CH, Anggård EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349-357. http://dx.doi.org/10.1111/j.1749-4486.2009.01973.x.
83. Merabishvili M, Pirnay J-P, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944. http://dx.doi.org/10.1371/journal.pone.0004944.
84. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay J-P. 2014. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 4:66-73.
85. Lu TK, Collins JJ. 2007. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA 104:11197-11202. http://dx.doi.org/10.1073/pnas.0704624104.
86. Lu TK, Collins JJ. 2009. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA 106: 4629-4634. http://dx.doi.org/10.1073/pnas.0800442106.
87. Edgar R, Friedman N, Molshanski-Mor S, Qimron U. 2012. Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl Environ Microbiol 78:744-751. http://dx.doi.org/10.1128/AEM.05741-11.
88. Yoichi M, Abe M, Miyanaga K, Unno H, Tanji Y. 2005. Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. J Biotechnol 115:101-107. http://dx.doi.org/10.1016/j.jbiotec.2004.08.003.
89. Mahichi F, Synnott AJ, Yamamichi K, Osada T, Tanji Y. 2009. Sitespecific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol Lett 295:211-217. http://dx.doi.org/10.1111/j.1574-6968.2009.01588.x.
90. Lin T-Y, Lo Y-H, Tseng P-W, Chang S-F, Lin Y-T, Chen T-S. 2012. A T3 and T7 recombinant phage acquires efficient adsorption and a broader host range. PLoS One 7:e30954. http://dx.doi.org/10.1371/journal.pone.0030954.
91. Heilpern AJ, Waldor MK. 2003. pIIICTX, a predicted CTXphi minor coat protein, can expand the host range of coliphage fd to include Vibrio cholerae. J Bacteriol 185:1037-1044. http://dx.doi.org/10.1128/JB.185.3.1037-1044.2003.
92. Merril CR, Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2:489-497. http://dx.doi.org/10.1038/nrd1111.